BioSpace News Archive

Rockwell Medical, Inc. today announced that the Company entered into an amended and restated products purchase agreement with its largest customer (the “Customer”).

Outlook Therapeutics, Inc. today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference being held in New York, NY on Tuesday, September 26, 2023 at 1:35 PM ET.

Nuvectis Pharma, Inc. today announced upcoming scientific presentations for NXP800 at the 2023 AACR Special Conference In Cancer Research: Ovarian Cancer (October 5-7, 2023, Boston, MA) and for NXP800 and NXP900 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (October 11-15, 2023 Boston, MA).

Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will host an Analyst & Investor Day event on Friday, October 13, 2023 from 1:00 p.m. to approximately 3:30 p.m. Eastern Time.

Vaxart, Inc. (Nasdaq: VXRT) today announced that senior management will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference in New York on Thursday, September 28, 2023 at 2:25 p.m. ET.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it will receive a payment of approximately $4.5 million as the latest installment under a grant agreement to advance the development of Daré’s investigational contraceptive DARE-LARC1.

NeurAxis, Inc., a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, reported financial results for the second quarter ended June 30, 2023.

89bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pegozafermin in patients with nonalcoholic steatohepatitis (NASH).

Accent Therapeutics today announced the appointments of Jason Sager, M.D. as Chief Medical Officer, Steven Mennen, Ph.D., as Vice President of Pre-Clinical Development and Stuart Ince, Ph.D. as Vice President of Program Leadership.

AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced the opening of its new global headquarters at 451 D Street in Boston, Mass.